Acasti Pharma (ACST) Reports Q4 Loss of $0.02
Get Alerts ACST Hot Sheet
Join SI Premium – FREE
Acasti Pharma (NASDAQ: ACST) reported Q4 EPS of ($0.02), versus ($0.02) reported last year.
Acasti is now corresponding with the FDA to determine next steps in the clinical development of CaPreĀ®, and obtain the required authorizations to proceed with such steps, including initiating a Phase III clinical trial. Such correspondence is meant to allow the FDA to provide feedback on Acasti's submissions and to answer specific questions on such submissions. Prior to a final response from the FDA, any exchange with them can take the form of written correspondence, discussions and potentially face-to-face meetings. The Company is working to respond to FDA feedback and will be working with them to determine resolution and direction needed to advance to Phase III.
For earnings history and earnings-related data on Acasti Pharma (ACST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2 reasons why Tesla stock fell on Thursday
- NaaS Technology Inc. (NAAS) Reports Q1 Loss of $0.29
- Torrid Holdings Inc. (CURV) Tops Q4 EPS by 4c, provides guidance
Create E-mail Alert Related Categories
Earnings, FDARelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!